Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B-cell chronic lymphoproliferative disorders from admixed benign B cells in four-color multiparameter flow cytometry

James Huang, Guang Fan, Yanping Zhong, Ken Gatter, Rita Braziel, Gary Gross, Antony Bakke

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

The diagnosis of B-cell chronic lymphoproliferative disorders is a great challenge when made in a background of polyclonal B cells. We studied the diagnostic usefulness of aberrant CD22 expression for differentiating neoplastic from benign B cells by 4-color flow cytometry. Of 56 cases of B-cell chronic lymphoproliferative disorders, we found that neoplastic cells showed aberrant CD22 expression in 39 (70%) of 56 cases, including chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma, hairy cell leukemia, and follicular lymphoma. In 4 cases, monoclonality was detected definitively only by evaluating the immunoglobulin light chain restriction in B cells with aberrant CD22 expression because numerous polyclonal B cells were present. Aberrant CD22 expression is a useful marker for detection of monoclonal B cells admixed with numerous benign polyclonal B cells.

Original languageEnglish (US)
Pages (from-to)826-832
Number of pages7
JournalAmerican journal of clinical pathology
Volume123
Issue number6
DOIs
StatePublished - Jun 2005

Keywords

  • Aberrant expression
  • B-cell chronic lymphoproliferative disorder
  • CD22
  • Flow cytometry

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B-cell chronic lymphoproliferative disorders from admixed benign B cells in four-color multiparameter flow cytometry'. Together they form a unique fingerprint.

  • Cite this